Navigation Links
Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting

SAN DIEGO, May 21, 2007 /PRNewswire/ -- Asenapine -- an investigational drug being developed by Organon, the human healthcare business unit of Akzo Nobel, for bipolar I disorder and schizophrenia -- was demonstrated to be more effective than placebo in treating acute manic and mixed episodes associated with bipolar I disorder, according to new Phase III results, from a study presented at the American Psychiatric Association's 2007 Annual Meeting.

In the three-week study, patients treated with either asenapine or olanzapine experienced significant improvements in acute mania symptoms, versus patients given placebo. Both asenapine and olanzapine demonstrated superiority versus placebo by the second day of treatment and maintained this benefit throughout the trial.

"The consequences of untreated mania in patients with bipolar disorder can be devastating to patients and their families. We need more effective and more tolerable treatments for these patients," said Robert Hirschfeld, M.D., Professor and Chair of the Department of Psychiatry and Behavioral Sciences at The University of Texas Medical Branch, Galveston. "The results of this trial suggest that asenapine is an attractive option for the acute treatment of mania because of its rapid onset of action and modest side effect profile."

Phase III Study Overview

The Phase III, double-blind, international trial conducted at 55 centers including 29 sites in the United States enrolled 488 patients with a manic (69%) or a mixed episode (31%) of bipolar I disorder and a baseline Young Mania Rating Scale (YMRS) score greater than or equal to 20 at entry. The YMRS is an 11-item scale used to evaluate manic symptoms; a score of at least 20 represents moderate-to-severe mania. Patients were randomly treated with asenapine (5-10 mg twice daily; average daily dose, 18.2 mg), olanzapine (5-20 mg once daily; average daily dose, 15.8 mg), or placebo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
2. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
5. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
6. Gabapentin Shown Effective for Fibromyalgia Pain
7. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
8. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
9. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
10. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
11. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases

Post Your Comments:
(Date:11/30/2009)...NTA, Georgia, November 30 /PRNewswire-FirstCall/ -...-based curriculum for direct support,professionals...ier and the, University of Minnesota,s Research a...d Disability Intensive Course (DIC) on "Cerebral P...ners to use as part of the online,curriculum. It i...
(Date:11/29/2009)... Elastography is an effective, convenient techniqu...tinguish cancerous breast lesions from benign resu... at the annual meeting of the Radiological Society...ields suspicious findings, physicians often use ul..., ultrasound has the potential to result in more b...
(Date:11/29/2009)..., Nov. 29 VIDA Diagnostics, a lead... the advanced analysis of pulmonary diseases, and ...invasive delivery of interventional oncology thera...tive agreement covering joint development and dist...iopsy system. ,, "Veran,s innovative instrumen...
Breaking Medicine Technology:Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 2Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 3Elastography Reduces Unnecessary Breast Biopsies 2Elastography Reduces Unnecessary Breast Biopsies 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 2VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 4New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 1New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 2Brain detects happiness more quickly than sadness 49206 1Brain detects happiness more quickly than sadness 49206 2Sands of Gobi Desert yield new species of nut cracking dinosaur 8871 1Sands of Gobi Desert yield new species of nut cracking dinosaur 8871 2
...Pa., Feb. 24 BioTrends is pleased to announce the...ds(TM): Uloric (R) . Takeda Pharmaceutical Co...roval for Uloric (R) (generic name: febuxostat)... for the chronic management of hyperuricemia assoc...or gout that has been approved in over forty years...
...Pa., Feb. 24 Kensey Nash Corporation (Nasdaq: K...estigational Device Exemption (IDE) application to...udy the use of the Company,s unique biomaterials t... of the knee. The clinical trial will utilize the ...of a proprietary bi-phasic, bioresorbable implant ...
Other Medicine Technology:Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4
(Date:11/30/2009)...ASDAQ OMX Copenhagen: “EXQ”) announced...od Screening Facility (ICCB-L) has been recognized...CB-L supports investigators at Harvard Medical Sch...r high-throughput screening of small molecule and ... MA and Copenhagen, Denmark (PRWEB) November 30, 2...
(Date:11/30/2009)...mber 30 Simbionix USA Corporation,...on systems, in collaboration,with GORE Medical Pro...o(TM),workshop for the first time at the upcoming ... Simbionix PROcedure Rehearsal Studio(TM) is the w...s to create practice scenarios based on their,pati...
(Date:11/30/2009)...evealed that beverage can pull-tabs were being swa...ufacturers to stay-tabs. But a study presented tod...ty of North America (RSNA) found that the new tabs...ving factors leading the change in beverage can co...t swallowing of the pull-tab and potential related...
(Date:11/30/2009)...ern Medical Center researchers have found that inf...ions associated with asthma. The findings, availab..., suggest that interventions by parent mentors c...specialized topical training can effectively redu... and missed adult workdays. , "Childhood asthma ...
(Date:11/29/2009)...re/ -- The following is an investment opinion rele.... ,, Intellivest Securities Research, Inc., ("I...published a Report on BioClinica, Inc. ( BIOC) whi...nology and medical device industries. A primary s...d submit medical imaging portions of their submiss...
Breaking Medicine News(10 mins):Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 4Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 3Health News:Beverage can stay-tabs pose swallowing risk 2Health News:Parent mentors can improve the asthmatic care of minority children, UT Southwestern researchers find 2Health News:Research Report on BioClinica, Inc. as Speculative Buy 2
...ot-long wall,along Madison Ave., located just sout...on as a new Guinness World Record. The mural was a...ership with Keep Indianapolis,Beautiful, Inc. (KIB...ubmitted the mural for consideration by Guinness, ...
...nfluenza Campaign to Promote Annual Vaccination , ... Influenza Vaccination Week (December 8-14); Urges... , KANSAS CITY, MO., Dec. 8 Health experts re...t every year. Locally, between 22,500 and 89,500 K...
... Foundation, New York State Health Foundation, For...ntial Social Investment Program and the Pioneer Po...g Investors to Join Leading Advocate for Independe...ORK (Business Wire EON) December 8, 2008 -- NEW Y...
...cell death and exerts resistance to chemotherapy h...xploited to target and kill the very tumor cells i...y of Illinois at Chicago show in a new study publi..."Akt is perhaps the most frequently activated onco...
... Pollution While EPA Shirks Responsibility , , ...Y released their study of schools where the outsid...cal contamination to young children and school sta...s been reporting since 2001. In several reports, ...
...(AUL) condemns a Montana trial court,s ruling that...ted suicide, and urges the state to appeal the dec... Dr. Charmaine Yoest, AUL President and CEO, sta...ied state insurance coverage for life-saving treat...
Other Medicine News:Health News:Lilly Global Day of Service Receives National and Local Recognition 2Health News:Lilly Global Day of Service Receives National and Local Recognition 3Health News:The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 2Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 3Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 4Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 5Health News:An Achilles heel in cancer cells 2Health News:If Your Child Says School Makes Him Sick - He Might Be Right 2Health News:Americans United For Life Denounces Montana Court's Assisted Suicide Decision, Urges Appeal 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: